new technologies competing with glp-1 medications 2025 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 The outlook for obesity from

AND, your friend Kim looks fabulous at the holiday party and tells you its the result of fill-in-the blank Glucagon like peptide-1 (GLP-1) Should you try it

X (Twitter): @drard

Projections now estimate that the cumulative revenue will surpass a staggering $470 billion by 20305

The appropriate MIC B12 dosage for injections varies from person to person and should be determined by a healthcare professional

The GLP-1 revolution: Novo Nordisk & Lilly now lead with semaglutide (Wegovy) & tirzepatide (Zepbound), showing double-digit weight loss percentages with fewer risks

It depends on your goals, your biology, your willingness to change habits, and how your body responds when the medication stops